We are retaining our narrow moat rating and fair value estimate.
We view shares as slightly undervalued but would wait for a better risk for reward entry point.
We are lowering our fair value estimate for the wide-moat firm.
We do not plan to make material changes to our fair value estimate for the narrow-moat financial services firm.
The wide-moat firm had a solid third quarter, and we are increasing our fair value estimate to $114.
We don't see any major impact to our fair value estimate based on the quarter's outperformance.
UnitedHealth shows momentum, but we do not expect to change our fair value estimate for the wide-moat firm.
We're reducing fair value estimate for the narrow-moat firm.
The narrow-moat firm is reducing commissions on U.S.-listed equities, ETFs, and options to $0.
We expect to decrease our fair value estimate for wide-moat Charles Schwab amid news of its pricing cut.